Compare Amphastar Pharmaceuticals Inc (AMPH) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs TORM plc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.54 (market cap $826.08M), while TORM plc trades at $29.21 (market cap $2.94B). The key difference: TORM plc is far larger — about 3.6× Amphastar Pharmaceuticals Inc's market cap, and TORM plc pays a 9.5% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | TRMD | |
|---|---|---|
Market Cap | $826.08M | $2.94B |
Sector | Health | Technology |
52-Week High | $30.81 | $34.87 |
52-Week Low | $16.87 | $17.46 |
Enterprise Value | $1.22B | $3.82B |
Dividend Yield | — | 9.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
TRMD trades at $29.48, up 5.06% today, with technical indicators showing a neutral bias and support near $28. The stock exhibits strong profitability with a 24.41% net margin and attractive valuation at a P/E of 8.65. Recent Q1 2026 earnings missed estimates but full-year guidance was raised, reflecting robust tanker market conditions. A $0.70 dividend for H1 2026 underscores shareholder returns.
Outlook remains positive given firm freight rates and strategic execution, though volatility from geopolitical factors and earnings misses pose risks. Analyst consensus is unanimously bullish, supporting upside potential if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
